NS-229

Phase 2

PharmaMar, S.A. (PHM.MC)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

PHM.MCPhase 2$26.2B

NS-229 Phase 2 Est. Readout

NS-229• Eosinophilic Granulomatosis With Polyangiitis45

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Eosinophilic Granulomatosis With Polyangiitis

View Full Landscape

Drug Information

Target Indication

Eosinophilic Granulomatosis With Polyangiitis

Clinical Trial

NCT06046222

Last updated: 7/1/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

PHM.MC

PharmaMar, S.A.

Operative Builders•Europe•BME

Related Pipeline

Relugolix Combination TabletPhase 3

Uterine Fibroids

Ingenol mebutate gel 0.05 %Phase 3

Actinic Keratosis

PerioChip ®Phase 3

Generalized Adult Periodontitis

LevocetirizinePhase 3

Dermatitis, Atopic

OxybutyninPhase 3

Urge Urinary Incontinence

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts